BioCryst Pharmaceuticals, Inc.
(NASDAQ:BCRX) today announced that
Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer
plans to provide a corporate summary and update regarding the Company’s clinical programs at the 7
Annual JMP Securities Healthcare Conference in New York on Thursday, July 12, 2012 at 9 a.m. Eastern Time.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website at
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and inflammatory diseases. BioCryst currently has two late-stage development programs:
, a viral neuraminidase inhibitor for the treatment of influenza, and
, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In addition, BioCryst is advancing two preclinical programs towards IND filings:
, a nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis C, and
, an oral inhibitor of plasma kallikrein for hereditary angioedema. Utilizing state-of-the-art structure-guided drug design and crystallography, BioCryst continues to discover innovative compounds with the goal of addressing unmet medical needs of patients and physicians. For more information, please visit the Company's website at
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at